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Abstract
Rationale Synergistic or supra-additive interactions between
the anorectics (dex)fenfluramine and phentermine have been
reported previously in the rat and in the clinic. Studies with 5-
HT2C antagonists and 5-HT2C knockouts have demonstrated
dexfenfluramine hypophagia in the rodent to be mediated by
actions at the 5-HT2C receptor. Given the recent FDA approv-
al of the selective 5-HT2C agonist lorcaserin (BELVIQ®) for
weight management, we investigated the interaction between
phentermine and 5-HT2C agonists on food intake.
Objectives This study aims to confirm dexfenfluramine-
phentermine (dex-phen) synergy in a rat food intake assay,
to extend these findings to other 5-HT2C agonists, and to
determine whether pharmacokinetic interactions could ex-
plain synergistic findings with particular drug combinations.
Methods Isobolographic analyses were performed in which
phentermine was paired with either dexfenfluramine, the 5-
HT2C agonist AR630, or the 5-HT2C agonist lorcaserin, and
inhibition of food intake measured in the rat. Subsequent
studies assessed these same phentermine-drug pair combina-
tions spanning both the full effect range and a range of fixed
ratio drug combinations. Satellite groups received single doses
of each drug either alone or in combination with phentermine,
and free brain concentrations were measured.
Results Dex-phen synergy was confirmed in the rat and ex-
tended to the 5-HT2C agonist AR630. In contrast, although
some synergistic interactions between lorcaserin and phenter-
mine were observed, these combinations were largely addi-
tive. Synergistic interactions between phentermine and dex-
fenfluramine or AR630 were accompanied by combination-
induced increases in brain levels of phentermine.
Conclusions Dex-phen synergy in the rat is caused by a
pharmacokinetic interaction, resulting in increased central
concentrations of phentermine.
Keywords Synergy . BELVIQ® . Lorcaserin . Isobologram .
Fen-phen
Introduction
Fenfluramine (Pondimin) and dexfenfluramine (Redux) are
anorectic agents which act to enhance serotonergic transmission
both through inhibition of 5-HT reuptake by the parent com-
pounds, and through their major circulating des-ethylated me-
tabolite, (dex)norfenfluramine, which is a 5-HT reuptake inhib-
itor, a 5-HT and noradrenaline releasing agent, and a potent
agonist at postsynaptic 5-HT2 receptors (Curzon et al. 1997;
Garattini et al. 1986; Mennini et al. 1991; Porter et al. 1999).
Both compounds were FDA-approved appetite suppres-
sants until 1997, when they were withdrawn due to their
association with cardiac valvular heart disease (Connolly
et al. 1997; http://www.fda.gov/Drugs/DrugSafety/
PostmarketDrugSafetyInformationforPatientsandProviders/
ucm179871.htm). While in clinical use, it had become
common practice for off-label co-administration of
fenfluramines with the anorectic sympathomimetic phenter-
mine (a combination commonly referred to as fen-phen). This
co-administration was apparently driven by two distinct ratio-
nales (see Wellman and Maher 1999). Firstly, that low dose
combinations of two drugs with distinct mechanisms of action
that share a clinical effect may enable maintenance of efficacy,
and thus the possibility of reduced, mechanism-based side
effects. Secondly, it was thought that the stimulant phenter-
mine may counteract sedation associated with fenfluramine
use. Anecdotal data soon emerged from clinical experience
that greater weight loss appeared to occur with the
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combination than would be expected with simply adding the
efficacy of either agent alone (Weintraub et al. 1984). Clinical
use of the combination subsequently exploded, such that
between 1992 and 1997, it was estimated that nearly 18
million prescriptions were written for fen-phen (Kassirer and
Angell 1998). The pharmacology of fen-phen on measures of
food intake in the rat was subsequently tested (Roth and
Rowland 1998, 1999; Wellman et al. 2003). These studies
assessed the interaction in both deprived and fed rats eating
standard lab chow or palatable sweetened milk after both
acute and chronic dosing, essentially confirming suspicions
from the clinic that the effect of the combination was more
than the sum of its constituent parts.
At around the same time, studies using both selective and
non-selective antagonists of the 5-HT2C receptor demonstrat-
ed that at least in the rodent, the effects of dexfenfluramine on
food intake were 5-HT2C mediated (Neill and Cooper 1989;
Grignaschi and Samanin 1992; Hartley et al. 1995; Curzon
et al. 1997; Vickers et al. 2001). This was consistent with
findings that a number of less than optimally selective 5-HT2C
receptor agonists such as mCPP and Ro 60–0175 reduced
food intake and body weight in rodents (for review see
Halford et al. 2005), that 5-HT2C receptor null mice are
hyperphagic and obese (Tecott et al. 1995), and that the
hypophagic effects of dexfenfluramine are significantly atten-
uated in such animals (Vickers et al. 1999). Clinical studies
also demonstrated that the 5-HT2C receptor preferential ago-
nist meta-chlorophenylpiperazine (mCPP) reduced hunger
and food intake in healthy, normal-weight volunteers (Walsh
et al. 1994) and hunger and body weight in the obese (Sargent
et al. 1997). These data, coupled with the withdrawal of the
fenfluramines in 1997, led to an industry-wide effort in the late
1990s to develop selective 5-HT2C agonists which would be
efficacious in the treatment of obesity and be devoid of the
valvulopathy which was believed to be associated with 5-
HT2B activation (Fitzgerald et al. 2000; Rothman et al. 2000).
This effort led to the development of lorcaserin
(BELVIQ®) which is now approved by the FDA for use in
weight management in obese (BMI >30) or overweight (BMI
27–30) patients with a comorbid condition. Lorcaserin is a
selective 5-HT2C agonist devoid of activity at the 5-HT2B
receptor at therapeutically relevant concentrations (Thomsen
et al. 2008; Unett et al. 2013), making it unlikely to affect heart
valve function. This lack of impact was confirmed by an
extensive development program of phase 2 and 3 clinical
studies which included prospective echocardiographic assess-
ments of valvular function (Weissman et al. 2013). Given that
dexfenfluramine-induced weight loss is 5-HT2Cmediated, and
that dex-phen effects appeared synergistic, the current studies
were designed to assess whether other, more selective 5-HT2C
agonists may act in a similar, synergistic manner.
The aims of the present work were fourfold: firstly, to
replicate previous findings in the literature suggesting
synergistic interactions between dexfenfluramine and phen-
termine, and secondly to determine whether these findings
extended to other agonists of the 5-HT2C receptor. For this, we
used two structurally distinct 5-HT2C agonists: an internal
standard from previous lead optimisation at Arena
Pharmaceuticals, AR630, and the FDA approved medication
lorcaserin (BELVIQ®). Various methods of measuring the
efficacy of drug combinations have been described previously
(see Tallarida 2001). We initially investigated the relationship
of these combinations using a standard isobolographic meth-
od, in which doses of each individual compound producing a
given effect (typically the ED50) are compared with combina-
tions of the two drugs together which produce the same effect.
In order to assess the robustness of these results, our third aim
was to compare the standard isobologramwith a more detailed
response-surface analysis as described previously (Tallarida
et al. 1999). This method simultaneously assesses drug inter-
actions across effect levels and at different concentration
ratios. Fourthly, we investigated whether any observed syner-
gy could be explained by drug interactions at the pharmaco-
kinetic level by measuring brain concentrations of all drugs in
the presence and absence of phentermine.
As reported previously, we confirm that dexfenfluramine
and phentermine act synergistically to reduce food intake in
the rat and extend this observation to the 5-HT2C agonist
AR630. In contrast, although some synergistic interactions
between lorcaserin and phentermine were observed, these
combinations were largely additive. We further demonstrate
that the synergy observed with dexfenfluramine and AR630 is
most likely driven by increases in central phentermine expo-
sure as a result of pharmacokinetic drug-drug interactions.
Materials and methods
All animal procedures were performed according to protocols
approved by the Arena Pharmaceuticals Animal Care and Use
Committee following NIH guidelines.
Drugs
Lorcaserin HCl hemihydrate and AR630 were synthesized at
Arena Pharmaceuticals Inc. AR630 is a 5-HT2C agonist which
is structurally distinct from lorcaserin (Fig. 1), although its 5-
HT2C agonist potency and selectivity is very similar
1.
Phentermine HCl and (S)+-fenfluramine (dexfenfluramine)
were purchased from Sigma Aldrich. All compounds were
dissolved in 20 % hydroxypropyl-beta-cyclodextrin (in sterile
1 AR630 functional activity: EC50 at 5-HT2C=10 nM (100 % intrinsic
activity (IA)); 5-HT2A=400 nM (60 % IA); 5-HT2B=1 μM (<10 % IA);
binding affinity (125I-DOI binding): Ki at 5-HT2C=4 nM; 5-HT2A=
120 nM; 5-HT2B=100 nM (internally generated data)
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water,w/v) andwere administered PO in a volume of 1mL/kg.
For combination treatments, lorcaserin, AR630, and dexfen-
fluramine powder were dissolved in phentermine solutions of
appropriate concentrations. All doses are expressed as those of
the free base.
Food intake studies
Animals and housing Male Sprague–Dawley rats (Harlan,
San Diego, CA) weighing 250–350 g were used for behav-
ioural studies. Upon arrival at the test facility, animals were
triple housed within a holding room controlled for humidity,
temperature, and light (lights off 1800–0600 hours). Rats
received food (2018SX Teklad Rodent Diet) and water ad
libitum unless stated otherwise. Over the course of all studies,
rats were re-used up to four times, with at least one week of
washout between tests. Rats were assigned to treatment
groups pseudo-randomly from test to test. One week prior to
initial drug testing, all rats were subject to a single food intake
test which was identical to all subsequent drug tests, except
that all rats received vehicle administration. Group size for all
studies, including brain sampling, was eight.
Food intake measurement Eighteen hours prior to food intake
testing (1600 hours), food was removed from home cages. On
the next day, animals were weighed and placed into cages with
grid floors at 1000 hours, and allowed to acclimate to these
cages for a 90-min period with free access to water and no
food. At 1130 hours, rats were injected with compounds via
oral gavage. Thirty minutes after injection (1200 hours), ani-
mals were allowed access to food. Food was then weighed at
30 min after food exposure (1 h after drug administration).
Upon test conclusion, rats were returned to home cages with
ad libitum access to food and water.
Measurement of tissue drug concentrations
In vivo methods employed for pharmacokinetic studies were
identical to those described for food intake studies except that
after dosing, rats were not placed into new cages with grid
floors. At 60 min after dosing (and 30 min after food access),
rats were anesthetized with isoflurane, blood was collected via
cardiac puncture, and brains were removed from the cranium.
Blood samples were dispensed into sodium heparinized vials
and capped and stored at 4 °C. Plasma was separated from
formed elements in blood by centrifugation (10 min at
3,000×g) and frozen. Brains were rinsed with ice-cold phos-
phate-buffered saline, blotted dry, weighed, and frozen.
Plasma and brain samples were stored at −80 °C prior to
bioanalytical analysis.
Bioanalytical method Brain samples were thawed on ice,
placed into 50 mL plastic conical tubes, and two volumes of
purified water/gram of brain was added. Brains were homog-
enized using a mechanical variable speed tissue homogenizer;
50 μL of brain homogenate was transferred to a 1-mL plastic
tube. A volume of acetonitrile (200 μL) containing internal
standard was added to brain homogenate, mixed by vortex,
and centrifuged (15 min at 3,700 rpm). Standard curves (from
1 to 2,500 ng/mL) and quality control samples (6, 60, 600 ng/
mL) were prepared in blank rat brain in a similar manner.
Supernatants were analysed for lorcaserin, AR630, phenter-
mine, dexfenfluramine, and the major metabolite of dexfen-
fluramine, norfenfluramine. Compound concentrations were
determined using a LC-MS/MS method. Analytes were sepa-
rated by reverse phase chromatography (Kinetex 3 × 30 mm,
C18, 2.6 μm, 100 Å, HPLC Column, Phenomenex, Torrance,
CA) using a binary gradient on a Shimadzu LC system
(Shimadzu Corp., Columbia, MD). The gradient consisted of
0.1 % formic acid in water and 0.1 % formic acid in acetoni-
trile with a flow rate of 650 μL/min. Detection of lorcaserin,
phentermine, dexfenfluramine, norfenfluramine, and internal
standards was achieved with electrospray ionization
(TurboIonSpray) in positive ion mode with an API 5000 LC/
MS/MS detector, (Applied Biosystems, Foster City, CA)
using MRM transitions of 196.1/144.2 Da (lorcaserin),
232.0/187.0 Da (dexfenfluramine), 150.0/133.0 Da (phenter-
mine), 204.1/187.0 Da (Norfenfluramine), and 202.1/
149.1 Da (lorcaserin-d6, internal standard).
Study 1, isobolograms Dexfenfluramine (0.25–4 mg/kg),
lorcaserin (0.5-8 mg/kg), phentermine (0.5-8 mg/kg), and
AR630 (1–16 mg/kg) were assessed for inhibition of food
intake. Doses were selected based upon previous in-house
experience with these compounds and ascended in twofold
steps. Two subsequent studies were run for each isobologram,
with dose–responses of each compound pair run in combina-
tion with a fixed, low dose of the other (phentermine 1 mg/kg;
AR630 1 mg/kg; dexfenfluramine 0.5 mg/kg; lorcaserin
1 mg/kg). To approximate the true experimental errors in these
experiments, a bootstrapping with replacement approach was
used (Huber 1981; Launer and Wilkinson 1979) in which five
Fig. 1 Chemical structures of
compounds used in the studies
Psychopharmacology (2015) 232:1973–1982 1975
data sets were generated from random samples of the
measured data points for both the individual dose–re-
sponses and for each drug/dose combination. These
were used to generate ED50 values and 95 % confidence
limits for all datasets which were subsequently plotted
in an isobologram. A line of additivity with confidence
limits was then drawn between the dose–responses of
each compound alone.
Study 2, response-surface analysis Methods are described in
detail elsewhere (Tallarida et al. 1999). Briefly, percent inhi-
bition relative to mean vehicle intake was calculated for each
rat in drug-treated groups from the dose–response studies and
logarithmic regressions applied. Resultant equations were
used to calculate relative potencies (R) of compound pairs
(lorcaserin-phentermine, dexfenfluramine-phentermine, and
AR630-phentermine) across the effect range (10–90 % inhi-
bition), with R values at the ED50 used as a basis for dose
selection in subsequent studies: Three separate studies for
each compound pair were then conducted, with ratios of doses
selected based upon R/2, R, and 2R. Actual doses were based
upon assumptions both from the isobolographic analysis and
previous experience with these drug combinations. These
were designed to capture the full dose–effect range (see
Table 1, columns 2 and 3).
The interaction index (α) was then calculated for percent
inhibition associated with each dose–pair combination: since
R differed according to percent inhibition of food intake for all
three compound pairs, logarithmic regressions were derived
for R across the effect range. These equations (R2=1 in all
cases) were used to calculate the R associated with each
percent inhibition for each subject, which in turn was used
to calculate the equivalent dose level of either dexfenflura-
mine, lorcaserin, or AR630 (Aeq) to produce that effect. The
actual dose (Acorr) of compound that produced that effect was
then calculated from the initial dose–response functions and
comparedwithAeq to provideα, whereα<1 suggests synergy.
Data analysis
To assess whether mean α values differed from 1 (no
synergy) in study 2, z scores were generated where
[z=(observed mean−expected mean (1))/standard error]
and compared with the appropriate t statistic (t(8)=2.31,
3.36 for p=0.95 and 0.99, respectively; Snedecor and
Cochran 1989). Whether alpha changed as a function of
drug ratio was assessed with a one-way ANOVA with R
as a factor, and the role of effect level in drug interac-
tions assessed by plotting percent inhibition of food
intake against alpha and performing a linear regression.
Lastly, brain drug concentrations were compared in the
presence or absence of the other analysed by one-way
ANOVA with combination treatment as a factor.
Results
Study 1, isobolographic analysis Phentermine, AR630, dex-
fenfluramine, and lorcaserin all dose-dependently reduced
food intake in the rat (Fig. 2), with selected dose ranges
effectively covering the full range of effect. Calculated ED50
values derived from logarithmic regressions were 2.45, 4.25,
1.44, and 1.98 mg/kg for phentermine, AR630, dexfenflura-
mine, and lorcaserin, respectively. These values and their
associated 95 % confidence intervals were plotted for each
of the phentermine-drug combinations, and a line drawn be-
tween the two points to form isobolograms with a line of
predicted additivity with associated confidence intervals
(Fig. 3). Subsequent studies in which fixed low doses of each
drug were combined with a dose–response of the other drug
from each combination yielded ED50 values and associated
95 % confidence limits which were added to the
isobolograms. Visual inspection of these indicated synergy
for all the dex-phen and AR630-phen combinations, and for
the two lorcaserin-phentermine combinations one additive
and one synergistic interaction.
Study 2: response-surface analysis Mean α values for the
dose pairs derived from all studies were 0.57, 0.83, and 1.04
(AR630-, dexfenfluramine-, lorcaserin-phentermine combina-
tions, respectively, Table 1). z scores derived for each drug pair
demonstrated all combinations of AR630 and phentermine to
differ significantly from 1, nearly half of the dexfenfluramine-
phentermine combinations, and two of the 15 lorcaserin-
phentermine combinations. Both of the significant α values
for the lorcaserin-phentermine combination were associated
with percent inhibition less than 10 %. ANOVA revealed no
effect of the ratio of drug combinations on α for either
dexfenfluramine- or lorcaserin-phentermine combinations
[F(2,12)=0.5 for both, NS] and a trend for AR630-
phentermine which failed to reach statistical significance
[F(2.12)=3.4, p=0.07]. No relationship was found between
inhibition of food intake and α for the lorcaserin-phentermine
combination (R2<0.01, F(1,14)=0.05, NS), a trend for the
AR630-phentermine combination (R2=0.16, F(1,14)=2.47,
p=0.13), and a strong correlation for dexfenfluramine-
phentermine (R2=0.85, F(1,14)=72.3, p<0.01).
Drug concentrations Administration of all compounds resulted
in brain concentrations with low variability between animals, and
within expected ranges (Table 2), although based on the single
60-min timepoint, rate of formation of norfenfluramine from
dexfenfluramine appeared to differ somewhat from other pub-
lished works (Mennini et al. 1985; Garattini et al. 1979). Neither
AR630 [F(1.14)=0.1, NS], lorcaserin [F(1,14)=0.2, NS], nor
dexfenfluramine [F(1,14)=0.1, NS] brain concentrations differed
when they were administered alone or as a mixture with phen-
termine. Similarly, measured concentrations of the major
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Table 1 Combination dose–effect data and calculated quantities for
AR630, dexfenfluramine, and lorcaserin in combination with
phentermine at three fixed ratio combinations. Rcalc, relative potencies
of the two drugs at the percent inhibition achieved;Aeq, equivalent dose of
compound A represented by phentermine dose; Acorr, dose of compound
A expected from dose–response studies to produce percent inhibition
achieved; α, interaction index where α<1=more than additive
Dose combinations (mg/kg)
AR630 Phentermine % Rcalc Aeq Acorr α
Set 1 0.27 0.32 3.44 1.39 0.72 1.07 0.71*
R=0.85 0.48 0.56 23.25 1.46 1.30 1.52 0.72**
0.85 1.00 60.91 1.70 2.55 4.75 0.47**
1.51 1.78 86.54 1.92 4.93 12.56 0.41**
2.69 3.16 98.82 2.01 9.05 18.09 0.50**
x 0.56
Set 2 0.41 0.24 30.61 1.55 0.78 2.39 0.40**
R=1.7 0.71 0.42 40.91 1.61 1.39 3.25 0.47**
1.28 0.75 73.15 1.83 2.65 8.45 0.33**
2.26 1.33 88.15 1.92 4.82 12.65 0.36**
4.03 2.37 95.01 1.99 8.73 16.16 0.55**
x 0.42
Set 3 0.58 0.30 13.78 1.45 1.01 1.45 0.72**
R=3.4 1.02 0.53 37.79 1.59 1.86 2.96 0.72
1.80 0.95 64.68 1.77 3.48 6.57 0.56**
3.20 1.69 83.27 1.90 6.41 11.40 0.60**
5.71 3.00 92.66 1.95 11.55 13.87 0.78**
x 0.67
Dose combinations (mg/kg)
Dexfenfluramine Phentermine % Rcalc Aeq Acorr α
Set 1 0.09 0.32 7.11 0.30 0.19 0.21 0.89
R=0.3 0.17 0.56 19.41 0.36 0.37 0.41 1.07
0.30 1.00 38.51 0.42 0.72 0.68 0.96
0.53 1.78 66.55 0.64 1.68 2.44 0.71**
0.95 3.16 98.96 0.93 3.89 7.89 0.48**
x 0.82
Set 2 0.14 0.24 – – – – –
R=0.6 0.25 0.42 19.08 0.36 0.40 0.41 1.12
0.45 0.75 40.61 0.47 0.80 0.92 1.13
0.80 1.33 69.57 0.67 1.69 2.74 0.69*
1.42 2.37 97.16 0.92 3.61 7.73 0.47**
x 0.85
Set 3 0.20 0.17 16.73 0.35 0.26 0.37 0.99
R=1.2 0.36 0.30 30.38 0.41 0.48 0.63 0.90
0.64 0.53 58.09 0.58 0.94 1.78 0.68
1.13 0.94 71.57 0.64 1.73 2.38 0.63**
2.01 1.68 98.84 0.93 3.57 7.94 0.44**
x 0.73
Dose combinations (mg/kg)
Lorcaserin Phentermine % Rcalc Aeq Acorr α
Set 1 0.13 0.32 5.04 0.76 0.37 0.61 0.63**
R=0.42 0.24 0.56 0.16 0.75 0.66 0.53 1.31
0.42 1.00 28.91 0.82 1.24 1.20 1.19
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circulating metabolite of dexfenfluramine, (dex)norfenfluramine
which were approximately sixfold that of the parent, did not
differ when dexfenfluramine was administered alone or with
phentermine [F(1,14)=1.0, NS].
This contrasts with brain concentrations of phentermine
when administered alone or in combination with other drugs:
Combining AR630 with phentermine led to a 3.8-fold increase
in brain concentrations of phentermine when compared to ad-
ministration alone [F(1,14)=26, p<0.01], and combining dex-
fenfluramine with phentermine led to a 2.6-fold increase
[F(1,14)=59, p<0.01]. These changes were not driven by
differential access to the central compartment, as brain/plasma
ratios of phentermine remained at approximately 13when dosed
alone or in the various combinations (data not shown). In
contrast, lorcaserin did not significantly alter phentermine con-
centrations in the brain (1.1-fold difference: F(1,14)=1.2, NS).
Discussion
Synergistic interactions between fenfluramine and phenter-
mine in the rat have been described previously (Roth and
Table 1 (continued)
0.75 1.78 58.03 0.88 2.32 2.73 0.94
1.33 3.16 83.17 0.95 4.32 5.57 0.81
x 0.98
Set 2 0.20 0.24 8.41 0.77 0.38 0.67 0.65*
R=0.86 0.35 0.42 4.58 0.76 0.67 0.60 1.06
0.63 0.75 29.89 0.82 1.24 1.23 1.11
1.12 1.33 46.61 0.86 2.26 1.98 1.45
1.99 2.37 68.45 0.91 4.15 3.67 1.17
x 1.09
Set 3 0.50 0.30 15.20 0.78 0.74 0.81 0.87
R=1.68 0.90 0.53 27.97 0.81 1.33 1.17 1.17
1.59 0.95 49.88 0.86 2.42 2.17 1.14
2.83 1.69 75.39 0.93 4.40 4.47 1.07






Fig. 2 Effect of oral administration of phentermine (a), dexfenfluramine (b), lorcaserin (c), and AR630 (d) on food intake in the rat. Left panels, absolute
intake after various doses; right panels, associated percent inhibition. **p<0.01 versus vehicle groups
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Rowland 1998, 1999;Wellman et al. 2003), although only one
of these studies formally tested the interaction. In this study,
Roth and Rowland (1999) performed isobolographic analyses
of sweetened milk intake after fen-phen administration, find-
ing synergy which was more robust in the fed than the fasted
state. Here, we recapitulate these data in deprived rats eating
standard lab chow, demonstrating statistically significant syn-
ergistic interactions. We also performed isobolographic anal-
yses on phentermine combinations with two structurally dis-
tinct 5-HT2C agonists, finding robust synergy with one
(AR630), and in the two interaction studies with lorcaserin
and phentermine both a moderate synergistic effect and simple
additivity. In order to further probe these interactions, we
pursued an additional method for assessing drug interactions
(Tallarida et al. 1999). Using this response-surface analysis,
we confirmed synergy with both dexfenfluramine and AR630
in combination with phentermine. Correlating percent
inhibition of food intake with the degree of interaction (α)
revealed inverse relationships for dexfenfluramine, such that
as inhibition of food intake (and thus dose) increased, so did
synergy: In the dex-phen combination, only the α values
associated with the two highest dose pairs in each study
differed significantly from 1. These interactions contrast with
lorcaserin, which in these response-surface studies were large-
ly additive: Two of 15 α values differed from one, and these
were both associated with low effect levels where one would
expect higher relative error. Given that the anorectic activity of
dexfenfluramine (Neill and Cooper 1989; Grignaschi and
Samanin 1992; Hartley et al. 1995; Curzon et al. 1997;
Vickers et al. 2001) and the 5-HT2C agonists (Thomsen et al.
2008) are 5-HT2C mediated, the differential findings between
the three compounds in combination with phentermine argue
against any simplistic mechanistic interaction, either at the
receptor level or downstream thereof. We therefore sought to
Fig. 3 Isobolographic plots for the anorectic effects at ED50 of three
phentermine-drug combinations. Left panel, dexfenfluramine; middle
panel, AR630; right panel, lorcaserin. Dotted lines and shaded areas
represent the predicted lines of additivity and associated 95 % confidence
intervals for all drug pairs. Additional points represent ED50 values and
associated 95 % confidence intervals derived from studies in which
phentermine (1 mg/kg) was combined with various doses of the other
compounds or where fixed doses of dexfenfluramine, AR630, or
lorcaserin were combined with various doses of phentermine
Table 2 Brain concentrations of AR630, dexfenfluramine, lorcaserin,
and phentermine measured 60 min after a single oral dose either alone or
in combination with phentermine. Right hand column represents the ratio
of drug concentrations when administered in a combination versus being
administered alone. In the dexfenfluramine study, the major circulating
metabolite of dexfenfluramine, norfenfluramine, was also measured. All
concentrations are mean±SEM, nanogram per gram. **p<0.01:
concentration measured in the combination versus concentration
measured after a single dose
Compound (mg/kg PO) Brain concentration (ng/g) Fold-change in concentration
Alone Combination
Phentermine (1) 226±32 866±120** 3.80**
AR630 (1) 82±14 92±25 1.12
Phentermine (1) 298±29 787±57 2.60**
Dexfenfluramine (0.5) 130±13 141±19 1.08
Norfenfluramine (−) 805±50 760±27 0.94
Phentermine (1) 298±29 335±18 1.12
Lorcaserin (1) 1,375±82 1,444±66 1.05
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assess potential pharmacokinetic interactions between the
drug-phentermine combinations as explanations for the inter-
actions observed. Using doses of the individual compounds
employed in the isobolographic analyses, we found that co-
administration of phentermine with either dexfenfluramine or
AR630 led to significantly higher concentrations of phenter-
mine (2.6- and 3.8-fold, respectively) in brain than when
dosed alone, whereas in combination with lorcaserin, levels
of phentermine were unchanged. In contrast, concentrations of
dexfenfluramine, AR630, and lorcaserin did not differ wheth-
er dosed alone or in combination with phentermine. This
demonstrated that where synergy did occur it was accompa-
nied by significant increases in central levels of phentermine
elicited by the drug combinations. The increased efficacy of
dexfenfluramine and AR630 in combination with phenter-
mine was therefore associated with pharmacokinetic interac-
tions. The fact that synergy with dexfenfluramine was more
apparent as dose increased is perhaps consistent with altered
drug concentrations being responsible for the synergy.
Additional studies would be needed to delineate the precise
dose–effect relationship for pharmacokinetic interactions.
Other behavioural and neurochemical endpoints have been
investigated with fen-phen in the rodent, including studies of
central neurotransmitter release (Rada and Hoebel 2000;
Balcioglu and Wurtman 1998; Shoaib et al. 1997), pain reac-
tivity (Wellman 2008), models of cocaine addiction (Rothman
et al. 1998; Glatz et al. 2002; Glowa et al. 1997), alcohol
consumption (Halladay et al. 2000), and fenfluramine-
induced neurotoxicities (Halladay et al. 1998). Some, but not
all of these have demonstrated synergistic interactions, and
this is perhaps not surprising given that for some of these
endpoints, such as conditioned place preference (Rothman
et al. 1998), dexfenfluramine and phentermine produce an
opposite pattern of effect which may cancel each other out.
For other endpoints, a PK explanation is clearly incompatible.
For example, Wellman (2008) reported a dose–responsive
effect of phentermine on pain reactivity in the hot plate assay,
and mild effects of dexfenfluramine only at high doses, with
isobolographic analyses demonstrating additive interactions
between the two. Further research is clearly needed to under-
stand these discrepancies.
The mechanism by which the pharmacokinetic interaction
occurs is not immediately obvious. Phentermine has two
major metabolites formed primarily by the action of the cyto-
chrome P450 (CYP) enzyme 3A4. This enzyme itself is not
extensively inhibited by phentermine, and 70–80 % of a dose
is excreted as unchanged phentermine in urine when admin-
istered alone. Although dexfenfluramine and AR630 interact
with various CYPs (von Moltke et al. 1998; Arena unpub-
lished observations), no mechanisms of drug metabolism or
clearance appear to differentiate dexfenfluramine and AR630
from lorcaserin or indicate a potential interaction with phen-
termine. The observed interactions were also not associated
with altered penetration of the central compartment, as brain/
plasma ratios remained consistent throughout all studies. It is
worth noting that similar interactions of phentermine with
other drugs have been observed in the clinic, as combining
the antiepileptic medication topiramate with phentermine
leads to a 42 % increase in phentermine area under the curve
in humans (Qsymia Drug Label information).
Although widely prescribed, thorough clinical investiga-
tions into the safety and efficacy of fen-phen in comparison
with its constituent medications are lacking, including an
assessment of possible pharmacokinetic interactions. The only
formal efficacy testing of fen-phen appears to have been
performed by Weintraub and colleagues (Weintraub et al.
1984; Weintraub 1994). Only in the former study was a
comparison made between the combination and monothera-
pies, and in this study different doses and daily treatment times
of phentermine and fenfluramine were applied alone or in
combination. The authors found that weight loss did not differ
amongst treatment groups, although, interestingly, they report
a ‘marked, sustained increase in total fullness (in patients
receiving the combination) whereas mean results from partic-
ipants receiving the other active treatments remained near
baseline and similar to the placebo response’. This suggests
that the combination was producing an effect distinct from
that produced by either product alone, again arguing against a
simple pharmacokinetic explanation.
While the isobolographic method relatively unambiguous-
ly identified synergy between phentermine and both dexfen-
fluramine and AR630, the result was somewhat ambiguous
with the lorcaserin-phentermine combination, with one point
demonstrating synergy and the other simple additivity. The
degree of potential synergy observed in any system may
depend not only on the drugs themselves but also on their
dose ratios (Tallarida et al. 1999). Therefore, in order to better
understand this relatively ambiguous result, we decided to
investigate the combination using a response-surface analysis.
In the response-surface analysis, all lorcaserin-phentermine
combinations were additive excepting two interaction terms.
These occurred where percent inhibition of food intake was
particularly low (<10 %) and therefore associated with high
relative error, and additionally were not associated with a
pattern of interaction either with dose ratio or efficacy, as in
both cases the next, higher dose combination resulted in lower
percent inhibition and the interaction terms exceeded one. The
isobolographic method assumes a simple linear relationship
between the ED50 values of two compounds, and deviation
from this ‘line of additivity’ indicates synergy or sub-
additivity (Breitinger 2012). This line essentially represents
a planar slice through the response surface of two drugs but
does not allow the investigation of synergy as a function of
dose ratios. If the response surface is complicated, an
isobolographic analysis may not allow the dissection of more
subtle features of the drug interactions or synergy. This
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includes potential differences in relative potency of the two
compounds across the effect level, thus not allowing for non-
linearity. A response surface analysis is a more exhaustive
investigation of the dose ratio dependence of synergy and may
allow more subtle features of synergy to be observed and
hypotheses against them to be developed to probe the mech-
anisms of synergy. Given that response-surface analysis stud-
ies require minimal additional resource, we therefore suggest
that these should be considered.
Given the experimental methods required to reliably detect
synergy, thorough investigation of synergistic drug interac-
tions in the clinic is extremely challenging. More importantly,
whilst synergy is a theoretically interesting proposition and a
mechanism for significantly increased efficacy, synergistic
interactions are not required for effective weight loss thera-
pies. Body weight maintenance is a highly regulated physio-
logical process mediated by multiple redundant systems, and
as such weight loss induces compensatory mechanisms which
work to oppose this loss (e.g. Ochner et al. 2013). Assuming
that additional weight loss achieved through drug combina-
tions is feasible and does not significantly increase side ef-
fects, whether this increase in weight loss is achieved through
an additive, synergistic, or even sub-additive interaction is of
little consequence to patients so long as absolute weight loss is
increased. Therefore, if a combination of lorcaserin and phen-
termine results in more weight loss in humans compared to
either lorcaserin or phentermine alone then it will be a wel-
come addition to the arsenal of pharmacotherapies for weight
loss, regardless of the nature of the interaction in humans.
To summarize, these data suggest that when central drug
concentrations are taken into account, interactions between
phentermine, dexfenfluramine, and other 5-HT2C agonists are
dose-additive when measuring inhibition of food intake in the
rat. This analysis suggests that in order to investigate the
nature of synergistic interactions properly, an understanding
of the pharmacokinetic properties of compounds alone and in
combination is essential.
Open Access This article is distributed under the terms of the Creative
Commons Attribution License which permits any use, distribution, and
reproduction in any medium, provided the original author(s) and the
source are credited.
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